cost of glp-1 medications Costly Drugs are Rarely Covered for Weight Loss by Marketplace Plans What is the 'real' cost
Description
Conclusion PWS is a complex disorder, and this syndromic obesity predisposes to an early risk of developing several health conditions as cardiometabolic diseases
Badaracco cited a Cornell study that showed GLP-1 users decreased spending by 5.5% within six months of taking the drugs, plus Circana data that highlighted drops in spending at convenience channels (-5.2%), mass (-3.9%) and grocery (-1%)
20 TECOS (2015) did not show an increased risk of HF in patients taking sitagliptin for treatment of type 2 diabetes
doi: 10.1186/s10194-024-01724-3
T1DM, type 1 diabetes mellitus
353 i2231
